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Abstract
Background: Progressive cell-mediated immunodeficiency with decrease of CD4+ lymphocyte
count to less than or equal to 200 cells/mm3 is a major risk factor for colonization with Candida
species and development of candidiasis. Oropharyngeal candidiasis may occur in up to 90% of
human immunodeficiency virus (HIV)-infected patients during the course of the disease. This study
is to determine the effect of prolonged highly active antiretroviral therapy (HAART) on
oropharyngeal colonization with Candida species and oral candidiasis.
Methods: A prospective, longitudinal follow-up study in HIV-infected patients receiving HAART.
Results: The mean CD4+ count increased from 232.5 to 316 cells/mm3 and the proportion of
patients whose CD4+ count less than 200 cells/mm3 decreased from 50.0% to 28.9% (p = 0.0003)
in patients receiving HAART for at least 2 years. The prevalence of oral candidiasis decreased from
10.6% to 2.1% (p = 0.004). The decrease in Candida colonization was less impressive, falling from
57.8% to 46.5 % (p = 0.06). Of the 142 patients enrolled in at least two surveys, 48 (33.8%)
remained colonized with Candida and 42 (29.6%) remained negative. In the remaining 52 patients,
34 switched from culture positive to negative, and an increase in CD4+ lymphocytes was noted in
91.2% of them. Among the 18 patients who switched from culture negative to positive, 61.1% also
demonstrated an increase in CD4+ lymphocyte count (p = 0.01).
Conclusion: These findings indicate that HAART is highly effective in decreasing oral candidiasis
in association with a rise in CD4+ lymphocyte counts, but only marginally effective in eliminating
Candida from the oropharynx.
Background
Mucosal candidiasis, including oropharyngeal, esopha-
geal, and vaginal candidiasis, is common among human
immunodeficiency virus (HIV)-infected patients [2,7].
Oropharyngeal candidiasis may occur in up to 90% of
HIV-infected patients during the course of the disease [9].
Progressive cell-mediated immunodeficiency with
decrease of CD4+ lymphocyte count to ≤ 200 cells/mm3 is
a major risk factor for colonization with Candida species
and development of candidiasis [1,3].
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The introduction of highly active antiretroviral therapy
(HAART) has led to a marked decrease in mortality and
morbidity [6,8] as well as the incidence of opportunistic
infections among HIV-infected patients [4]. It is less clear
whether immune reconstitution protects HIV-infected
patients from colonization with Candida species. These
three prospective longitudinal follow-up surveys (in
1999, 2001, and 2002) were designed to determine the
effect of prolonged HAART on oropharyngeal candidiasis
and colonization with Candida species in Taiwan.
Methods
HIV-infected patients followed regularly at the acquired
immune deficiency syndrome (AIDS) clinic at the
National Taiwan University Hospital (NTUH) were
enrolled in the study. The patients underwent three
rounds of surveys for oral candidiasis in 1999, 2001, and
2002. A standardized case form was used to retrieve
demographic information, CD4+ lymphocyte counts
obtained from dates nearest to the survey culture dates
and viral load. Hospitalization and receipt of antibiotics
and anti-fungal drugs within three months of sampling
were also recorded. For patients participated in all three
surveys, the clinical data of 1999 and 2002 were used for
analysis. Inclusion criteria consisted of continuous receipt
of HAART, at least two complete clinical and laboratory
observations during the study period and verbal informed
consent. The institutional review board of the NTUH has
approved the study.
Cultures of the oropharyngeal and tonsillar regions were
performed using a dry sponge swab (EZ Culturette, Becton
Dickinson, Sparks, MD) as described previously [3,5]. The
swabs collected in 1999 were plated on Sabouraud Dex-
trose Agar (SDA) medium with chloramphenicol and gen-
tamicin (BBL), and those collected in 2001 and 2002 were
plated on Chromagar Candida (BBL). All cultures were
incubated at 30°C. For diagnosis, the isolates were first
tested by the germ tube assay. The VITEK Yeast Biochemi-
cal Card (YBC, bioMerieux, St. Louis, MI, USA) was used
to identify isolates that failed to form germ tubes. The API-
32C (Marcy, L'ETOILE, France) was used to assess the
results when the VITEK-YBC showed less than 90% confi-
dence.
Plasma viral RNA load (PVL) and CD4+ lymphocyte
count were usually determined at the baseline at the diag-
nosis of HIV infection and/or immediately before initia-
tion of antiretroviral therapy. In those who did not initiate
antiretroviral therapy, those tests were conducted on 4–6
month intervals; in those who did initiate the antiretrovi-
ral therapy, those tests were first conducted at 1 month
after the beginning of the therapy, and then onto 4-month
intervals regularly. When the therapy is to be changed due
to virologic failure, testing protocol would be the same as
those who initiated therapy for the first time. PVL were
quantified using reverse transcriptase-polymerase chain
reaction (RT-PCR, Roche Amplicor, version 1.5) with a
detection limit of 400 copies/ml and CD4+ counts were
Table 1: Characteristics of 142 patients receiving HAART
First survey Subsequent survey
Group 1 (N = 11) 2 (N = 83) 3 (N = 48) Total 1 (N = 11) 2 (N = 83) 3 (N = 48) Total p
Characteristic number of isolates (percentage) number of isolates (percentage)
CD4+ count > 
200
5 (45.5) 42 (50.6) 24 (50) 71 (50) 10 (10.9) 55 (66.3) 36 (75) 101 (71.1) 0.0003
CD4+ count ≤ 
200




7 (63.3) 48 (57.8) 27 (56.3) 82 (57.7) 6 (54.5) 37 (44.6) 23 (47.9) 66 (46.5) 0.06
Oral 
candidiasis
1 (9.1) 10 (12) 4 (8.3) 15 (10.6) 0 2 (2.4) 1 (2.1) 3 (2.1) 0.004
Hospitalized* 1 (9.1) 15 (18.1) 10 (20.8) 26 (18.3) 1 (9.1) 4 (4.8) 1 (2.1) 6 (4.2) 0.0002
Received anti-
fungal drugs*
2 (18.2) 10 (12) 7 (14.6) 19 (13.4) 0 3 (3.6) 1 (2.1) 4 (2.8) 0.002
Received 
antibiotics*
9 (81.8) 29 (34.9) 32 (66.7) 70 (49.3) 2 (18.2) 16 (19.3) 4 (8.3) 22 (15.5) < 0.0001
Plasma viral 
load (> 50 
copies/ml) (N 
= 82)
ND 59 (72) ND ND ND 22 (26.8) ND ND < 0.0001
* Within three months of the Candida culture, p value is calculated by total number of isolates
Group 1, patients only in 1999 and 2001; group 2, patients only in 2001 and 2002; and group 3, patients in all three years.BMC Infectious Diseases 2006, 6:8 http://www.biomedcentral.com/1471-2334/6/8
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determined using FACFlow (Becton Dickinson). Oropha-
ryngeal candidiasis was characterized by painless, creamy
white, plaque-like lesions on the buccal or oropharyngeal
mucosa or tongue surface.
All clinical and laboratory data were entered into a rela-
tional database designed for Microsoft Access 97 (Micro-
soft, Redland, WA). The statistical significances of the
differences in frequencies and proportions were deter-
mined by the Chi-square test with Mantel-Haenszel cor-
rection.
Results
During this four-year-long study, there were 142 patients
met the inclusion criteria. The mean age for them at the
initial survey was 38.8 years and there were 93.7% males.
Of these patients, 41 received the first HAART when they
enrolled in this study. Among the remaining, 52, 31, 9, 8,
and 1 patients have participated the HAART program for
1, 2, 3, 4, and 7 years, respectively, before they enrolled in
this study. There were 11 patients participating only in the
1999 and 2001 surveys (group 1), 83 patients only in the
2001 and 2002 surveys (group 2), and 48 patients in all
three surveys. Upon follow-up, the mean CD4+ lym-
phocyte count rose from 232.5 ± 180.1 cells/mm3 to 316
± 197.0 cells/mm3. The proportion of patients whose
CD4+ count was ≤ 200 cells/mm3 decreased from 50.0%
to 28.9 % (p = 0.0003) (Table 1). There was also a signif-
icant decrease between the initial and follow-up surveys
in the percentage of patients who were hospitalized or
received antifungal drugs and antibiotics (Table 1). These
findings were independent of age and gender.
In all, the prevalence of oral candidiasis decreased from
10.6 to 2.1 % (p = 0.004), while the change in prevalence
of Candida colonization was less impressive, falling from
57.8% to 46.5 % (p  = 0.06). Among the patients, 48
(33.8%) remained colonized with Candida  and 42
(29.6%) remained negative. And in the remaining 52
patients, 34 switched from culture positive to negative
alone with an increase in CD4+ cells in 91.2% of them.
Among the 18 patients switching from culture negative to
positive, 61.1% also demonstrated an increase in CD4+
counts. In the total 284 samplings, there were 65 with
CD4+ counts ≤ 200 and were also culture-positive for
Candida whereas there were 47 with CD4+ counts ≤ 200
but were culture-negative (p = 0.11). Thus, in addition to
the CD4+ count, some other factors appear to have signif-
icant effects on oral colonization by Candida.
Discussion
We have previously shown that hospitalization and
receipt of antibiotics were risk factors for oropharyngeal
colonization by Candida and that a low CD4+ lymphocyte
count (≤ 200 cells/mm3) was a risk factor for developing
oral candidiasis [3]. It is well known that HIV-infected
patients are more likely to be colonized by Candida than
healthy individuals [3,7]. Our current findings are consist-
ent with previous reports. The dramatic reduction in oral
candidiasis found in this study is also consistent with
reports that HAART markedly decreases mortality and
morbidity as well as the incidence of AIDS-defining
opportunistic infections [6,8]. It was therefore somewhat
surprising to find that the frequency of oropharyngeal col-
onization by Candida, although close to significant (p =
0.06), was not as dramatically decreased. Possible expla-
nations include poor compliance, failure to reduce the
viral load and raise the CD4+ lymphocyte count or disso-
ciation between colonization and infection. The most
likely scenario is that most patients receiving HAART con-
tinue to be colonized by Candida, but do not develop oral
candidiasis.
Conclusion
Increase of the CD4+ lymphocyte counts is required but
not sufficient to protect HIV-infected patients from colo-
nization by Candida. Further studies are needed to better
define the relationship between Candida colonization and
infection in patients with AIDS.
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